Try it
PSM · Epidemiology: censoring in survival analysis
Sample itemIn a Kaplan-Meier analysis of a cancer drug, one patient moves abroad at month 14 with no information about his later status. How should he be handled?
Original practice item, not a recalled exam question. Nothing here is recorded.
The answer and the reasoning
D. Censored at 14 months, contributing follow-up until then
A patient lost to follow-up is censored: his time at risk up to the last contact is used, and nothing is assumed after it. Counting him dead or alive would bias survival downwards or upwards. Censoring lets incomplete follow-up still contribute information.
Option by option
A. Excluded entirely from the analysis
Complete exclusion wastes information and can bias results.
B. Counted as dead at 14 months
Counting him as dead would underestimate survival.
C. Counted as alive until the end of the study
Counting him alive to the end overestimates survival.
D. Censored at 14 months, contributing follow-up until then (correct)
Correct. Censoring uses the information available until he was lost.
Source note: Original NextPrep sample item — pending expert review. This item is original practice material awaiting independent expert review, so confirm important facts in a standard textbook.
More PSM questions
- BiostatisticsOf 200 people who truly have a disease, a screening test is positive in 180. What is the…
- Environmental healthAfter one hour of contact time, what residual free chlorine level is generally recommend…
- EpidemiologyWhich study design is the most efficient for investigating risk factors of a rare disease?
- BiostatisticsIn hypothesis testing, a Type I error is: